On March 4, 2021 Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell–based protein expression system, reported that the Company’s management will participate and present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, a virtual conference taking place March 9–10, 2021 (Press release, Protalix, MAR 4, 2021, View Source [SID1234576133]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dror Bashan, the Company’s President and Chief Executive Officer, has recorded a presentation that will be available beginning Tuesday, March 9, 2021 at 7:00 am ET at the following website: View Source Those interested in registering for the conference can do so here: View Source

A webcast of the presentation will also be available at www.protalix.com on the event calendar page, View Source A replay of the presentation will be archived and available for approximately 90 days following the presentation.